Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
(Correcting investment manager of International Biotechnology Trust PLC.)
International Biotechnology Trust PLC - biotechnology and healthcare sector-focused alternative investment fund, managed by Schroders - On May 8 reports net asset value total return of 11% in six months to February 29, outperforming reference index which rises 8.2%. NAV per share rises 8.9% to 748.90 pence from 687.51p at end of August. The trust had paid a first interim dividend of 13.90p in January, down 0.7% from 14.00p. Its dividend policy is to make payments equivalent to 4% of NAV. It plans to make the declaration for the second dividend of the year in July, before payment in August. Looking ahead, Chair Kate Cornish-Bowden says: ‘The science and innovation in the drug development sector is more exciting than ever. The number of new clinical trials registered in 2023 reached a new high, as novel techniques and technology including gene therapy, cell therapy and RNA therapeutics gained momentum. The M&A outlook remains bright, and the need for large pharmaceutical companies to fill their pipelines is as great as ever. Relative valuations in the small and mid-cap biotechnology companies are compelling.’
Current stock price: 622.00 pence
12-month change: down 5.9%
Copyright 2024 Alliance News Ltd. All Rights Reserved.